Serious problem detected in Turkey's drug tracking system

25 May 2010

A serious problem has been detected in the Drug Tracking System (İTS), launched in Turkey on May 16, 2010, which, if successful, is expected to largely prevent drug counterfeiting and off-record transactions in the pharmaceutical sector.

An investigation conducted by the Association of Research-Based Pharmaceutical Companies (AİFD), found that some of the 2D-barcode readers, currently used by pharmacies for reading the 2D-barcodes, are unable to perform this function, resulting in a situation where products which have been registered in the İTS erroneously appear as though they are not registered.

Prior to the May 16 introduction, Turkey's pharmaceutical industry had expressed concerns about bringing forward the deadline shift from year-end to June 1, 2010 for banning the sale of products without a 2D-barcode in connection with the İTS, warning of labelling mix-ups and malicious fraud for profit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >